Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer

Transforming growth factor-β (TGF-β) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-β are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling system that includes two types of cell surface receptors and intracellular signal transducers, the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative TGF-β responses in tumor cells, including mutations in components of the signaling system and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory molecules. Some of these mechanisms will be discussed, with emphasis on their potential involvement in breast tumorigenesis.

[1]  J. Massagué,et al.  SMADs: mediators and regulators of TGF-β signaling , 1998 .

[2]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[3]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[5]  S. Hughes,et al.  Activation of the c-ski oncogene by overexpression , 1991, Journal of virology.

[6]  W. Bodmer,et al.  Screening SMAD1,SMAD2, SMAD3, andSMAD5 for germline mutations in juvenile polyposis syndrome , 1999, Gut.

[7]  E. Gabrielson,et al.  The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. , 1999, Cancer research.

[8]  H. Hollema,et al.  Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.

[9]  N. Nomura,et al.  Expression of the c-ski proto-oncogene in human melanoma cell lines. , 1993, Melanoma research.

[10]  K. Irie,et al.  The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3 , 1998, Nature.

[11]  A. Roberts,et al.  Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. , 1998, Genes & development.

[12]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[13]  J. Willson,et al.  Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells , 1994 .

[14]  A. Klibanski,et al.  Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[15]  Luzhe Sun,et al.  Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells* , 1996, The Journal of Biological Chemistry.

[16]  R. Lotan,et al.  DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. , 1996, Cancer research.

[17]  Qiang Zhou,et al.  The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. , 1999, Genes & development.

[18]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[19]  N. Wake,et al.  Mutation analysis of the Smad3 gene in human ovarian cancers. , 1999, International journal of oncology.

[20]  R. Weinberg,et al.  Interaction of the Ski Oncoprotein with Smad3 Regulates TGF-β Signaling , 1999 .

[21]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Kouzarides Histone acetylases and deacetylases in cell proliferation. , 1999, Current opinion in genetics & development.

[23]  R. Wieser,et al.  Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia , 1998, Leukemia.

[24]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[25]  K. Kinzler,et al.  Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.

[26]  J. Yokota,et al.  Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. , 1997, Cancer research.

[27]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[28]  G. Nucifora The EVI1 gene in myeloid leukemia , 1997, Leukemia.

[29]  H. Ostrer,et al.  TβR-I(6A) Is a Candidate Tumor Susceptibility Allele , 1999 .

[30]  A. Green,et al.  Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. , 1999, International journal of oncology.

[31]  T. Mitsudomi,et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[32]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[33]  D. Dillon,et al.  The molecular biology of breast cancer: accelerating clinical applications. , 1998, Critical reviews in oncogenesis.

[34]  S. Nishizuka,et al.  MAD‐related Genes on 18q21.1, Smad2 and Smad4, Are Altered Infrequently in Esophageal Squamous Cell Carcinoma , 1997, Japanese journal of cancer research : Gann.

[35]  H. Friess,et al.  Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. , 1999, Biochemical and biophysical research communications.

[36]  K. Luo,et al.  Negative Feedback Regulation of TGF-β Signaling by the SnoN Oncoprotein , 1999 .

[37]  R. Derynck,et al.  Transcriptional Activators of TGF-β Responses: Smads , 1998, Cell.

[38]  Z. Hall Cancer , 1906, The Hospital.

[39]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[40]  C. Heldin,et al.  Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. , 1998, Biochemical and biophysical research communications.

[41]  D. Welch Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential , 1990 .

[42]  Adriana,et al.  Resistance to Transforming Growth Factor 1 and Activin Due to Reduced Receptor Expression in Human Breast Tumor Cell Lines ’ , 2005 .

[43]  C. Marshall,et al.  How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.

[44]  A. Andrén-sandberg,et al.  Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer , 1999, Genes, chromosomes & cancer.

[45]  S. Ishii,et al.  Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. , 1999, Genes & development.

[46]  Y. Yazaki,et al.  The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. , 1995, Oncogene.

[47]  J. Kleeff,et al.  Transfection of the type I TGF‐β receptor restores TGF‐β responsiveness in pancreatic cancer , 1998 .

[48]  H. Taguchi,et al.  Analysis of the Smad2 gene in hematological malignancies , 1998, Leukemia.

[49]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[50]  S. Horiike,et al.  Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. , 1996, Leukemia.

[51]  J. Massagué,et al.  A Smad Transcriptional Corepressor , 1999, Cell.

[52]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Heldin,et al.  Expression of Smad proteins in human colorectal cancer , 1999, International journal of cancer.

[54]  K. Miyazono,et al.  Induction of Smad6 mRNA by bone morphogenetic proteins. , 1998, Biochemical and biophysical research communications.

[55]  H. Lodish,et al.  A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. , 1999, Blood.

[56]  Y. Yatabe,et al.  Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[57]  J. Massagué,et al.  Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-β Antiproliferative Responses in Colon Cancer Cells* , 1999, The Journal of Biological Chemistry.

[58]  J. Willson,et al.  Expression of transforming growth factor‐β receptor type II and tumorigenicity in human breast adenocarcinoma MCF‐7 cells , 1998 .

[59]  D. Alberts,et al.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.

[60]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[61]  A. Kilbey,et al.  Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[62]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[63]  L. Aaltonen,et al.  SMAD genes in juvenile polyposis , 1999, Genes, chromosomes & cancer.

[64]  N. Nomura,et al.  Isolation of human cDNA clones of ski and the ski-related gene, sno. , 1989, Nucleic acids research.

[65]  H. Moses,et al.  Transforming Growth Factor β and Cell Cycle Regulation , 1995 .

[66]  K. Miyazono,et al.  c-Ski Acts as a Transcriptional Co-repressor in Transforming Growth Factor-β Signaling through Interaction with Smads* , 1999, The Journal of Biological Chemistry.

[67]  J. Barber Medical genetics: advances in brief , 1995 .

[68]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Y. Yazaki,et al.  The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. , 1998, Blood.

[70]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[71]  R. Weinberg,et al.  SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Mohammed A. Khan,et al.  Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β , 1997, Oncogene.

[73]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[74]  J. Massagué,et al.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.

[75]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[76]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[77]  Kathleen R. Cho,et al.  A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. , 1995, Cancer research.

[78]  S. Kern,et al.  Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. , 1996, Cancer research.

[79]  A. V. van Kessel,et al.  Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts , 1996, International journal of cancer.

[80]  Y. Yuasa,et al.  Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. , 1998, Cancer letters.

[81]  D. Demetrick,et al.  Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. , 1996, Biochemical and biophysical research communications.

[82]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[83]  M. Reiss,et al.  Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. , 1993, Critical reviews in oncogenesis.

[84]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[85]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[86]  Y. Nagamachi,et al.  Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.

[87]  C. Niehrs,et al.  Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.

[88]  R. L. Baldwin,et al.  Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition , 1996, International journal of cancer.

[89]  H. Kuwano,et al.  No mutations of the Smad2 gene in human sporadic gastric carcinomas. , 1999, Japanese journal of clinical oncology.

[90]  Mansoor M Ahmed,et al.  Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas , 1998, Genes, chromosomes & cancer.

[91]  Scott E. Kern,et al.  Mad-related genes in the human , 1996, Nature Genetics.

[92]  J. Slingerland,et al.  Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer , 2000, Breast Cancer Research.

[93]  H. Kuwano,et al.  Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. , 1999, International journal of oncology.

[94]  O. Cussenot,et al.  Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer , 1999, The Prostate.

[95]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[96]  C. Benz,et al.  Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.

[97]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[98]  H. Lodish,et al.  Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia , 1997 .

[99]  J. Massagué,et al.  Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. , 1998, Genes & development.

[100]  K. Naito,et al.  Endometrial expression of cellular protooncogene c‐ski and its regulation by estradiol‐17β , 1999, FEBS letters.

[101]  Yusuke Nakamura,et al.  Mapping of a Breast Cancer Tumor Suppressor Gene Locus to a 4‐cM Interval on Chromosome 18q21 , 1997, Japanese journal of cancer research : Gann.

[102]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[103]  F. Pouliot,et al.  Expression profile of agonistic Smads in human breast cancer cells: Absence of regulation by estrogens , 1999, International journal of cancer.